奧密克戎繼續擴散 港股抗疫板塊持續走高 君實生物漲超17%
格隆匯1月14日丨跟隨A股市場的拉昇走勢,港股抗疫概念股隨之走高,君實生物漲超17%,康希諾生物、復星醫藥、歌禮制藥、東陽光藥漲超34%,石藥集團和白雲山漲超2%,中國生物製藥、四環醫藥漲超1%。奧密克戎新冠病毒正進一步全球性擴散。為應戰奧密克戎,美國總統拜登指示美國政府採購額外的5億份COVID-19檢測試劑盒,以幫助滿足在奧密克戎變種病毒擴散期間全國各地的需求,同時還將免費提供最具防護性的N95口罩。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.